Open Access
ARTICLE
Astragaloside IV improves melanocyte differentiation from mouse bone marrow mesenchymal stem cells
XINGYU MEI, ZHOUWEI WU, CHENGZHONG ZHANG, YUE SUN, WEIMIN SHI*
Department of Dermatology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
* Corresponding Author: Weimin Shi,
BIOCELL 2021, 45(6), 1551-1559. https://doi.org/10.32604/biocell.2021.015376
Received 14 December 2020; Accepted 01 February 2021; Issue published 01 September 2021
Abstract
Vitiligo results in an autoimmune disorder destructing skin pigment cells, melanocytes (Mcs). This study aimed
to investigate whether Astragaloside IV (AIV) could efficiently induce differentiation of bone marrow mesenchymal stem
cells (BMMSCs) into Mcs. BMMSCs were induced and differentiated into Mcs with 0.1, 0.2, and 0.4 mg/L AIV during
150-day. Morphologic changes of differentiated cells were observed. Levels of some melanocytic specific genes (
TRP-1,
TRP-2,
MART-1,
Mitf) were measured with quantitative polymerase chain reaction (qPCR) at 90, 120, and 150 days
of induction. After 90-day induction, the differentiated cells with 0.4 mg/L AIV demonstrated the typical morphology
of Mcs, positive 3,4 dihydroxyphenylalanine staining, and positive staining of TRP-1, TRP-2, MART-1, and Mitf.
After 90- and 120- days’ induction with 0.4 mg/L AIV,
TRP-1 expression was significantly elevated (
p < 0.01), and
TRP-2 expression was significantly increased in 0.4 mg/L AIV-treated group compared to negative control (
p < 0.01),
0.1 mg/L (
p < 0.01), and 0.2 mg/L (
p < 0.01) AIV-treated groups. Moreover,
MART-1 expression was significantly
up-regulated in 0.4 mg/L AIV-treated group compared to negative control, but without difference compared to 0.1
mg/L (
p > 0.05) and 0.2 mg/L (
p > 0.05) AIV-treated groups. During 90 to 150- day induction, there were no
significant differences for Mitf levels between AIV-treated groups and negative control (
p > 0.05). In conclusion,
90-day induction with 0.4 mg/L AIV up-regulated
TRP-1,
TRP-2, and
MART-1 expression, indicating that AIV can
efficiently induce Mcs differentiation from BMMSCs. These results provide experimental and theoretic evidence for
AIV application in clinical vitiligo repigmentation treatment.
Keywords
Cite This Article
APA Style
MEI, X., WU, Z., ZHANG, C., SUN, Y., SHI, W. (2021). Astragaloside IV improves melanocyte differentiation from mouse bone marrow mesenchymal stem cells. BIOCELL, 45(6), 1551-1559. https://doi.org/10.32604/biocell.2021.015376
Vancouver Style
MEI X, WU Z, ZHANG C, SUN Y, SHI W. Astragaloside IV improves melanocyte differentiation from mouse bone marrow mesenchymal stem cells. BIOCELL . 2021;45(6):1551-1559 https://doi.org/10.32604/biocell.2021.015376
IEEE Style
X. MEI, Z. WU, C. ZHANG, Y. SUN, and W. SHI "Astragaloside IV improves melanocyte differentiation from mouse bone marrow mesenchymal stem cells," BIOCELL , vol. 45, no. 6, pp. 1551-1559. 2021. https://doi.org/10.32604/biocell.2021.015376